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INTRODUCTION
The appendix is one of  the most common single site for 
carcinoid tumor[1]. Histopathologically, appendiceal carci-
noid tumor is mostly enterochromaffi n (EC) cell type and 
derives from a subepithelial cell population, which is differ-
ent from neuroendocrine tumor in other sites[2]. Although 
rare and usually detected incidentally in appendectomy, it is 
considered the most common type of  appendiceal primary 
malignant lesion, and is found in 0.3%-0.9% of  patients 
undergoing appendicectomy[3]. This tumor rarely presents 
with metastases[4,5]. Despite the fact that it is among the 
most frequently occurring carcinoids, in surgical practice 
most surgeons may encounter only one or two such lesions 
during their career[6]. Therefore, it is important to defi ne a 
correct management of  such a rare tumor. The authors re-
port here a series of  5 appendiceal carcinoid tumors found 
during appendectomy in a single centre and compared this 
experience with the recent literature on this subject.
MATERIALS AND METHODS
A retrospective review of  all appendectomies was 
performed from January 2000 to May 2004 in a single 
department of  abdominal surgery in a tertiary referral 
center (CHU Sart Tilman, University of  Liège, Belgium). 
The data of  the patients who were histologically reported 
to have carcinoid tumor of  the appendix were further 
reviewed for demographic characteristics, cl inical 
presentation, histopathology, operative reports and follow-
up.
RESULTS
A total of  1237 patients underwent appendectomy during 
the study period (991 for acute appendicitis or appendicu-
lar syndrome and 246 during other abdominal procedures). 
Out of  these 1237 patients, 5 (0.4%) were found to have 
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Abstract
AIM: To report the experience of the CHU Sart Tilman, 
University of Liège, Belgium, in the management of 
appendiceal carinoid tumor.
METHODS: A retrospective review of 1237 appendecto-
mies performed in one single centre from January 2000 
to May 2004, was undertaken. Analysis of demographic 
data, clinical presentation, histopathology, operative re-
ports and outcome was presented. 
RESULTS: Among the 1237 appendectomies, 5 appen-
diceal carcinoid tumors were identifi ed (0.4%) in 4 male 
and 1 female patients, with a mean age of 29.2 years 
(range: 6-82 years). Acute appendicitis was the clinical 
presentation for all patients. Four patients underwent 
open appendectomy and one a laparoscopic procedure. 
One patient was reoperated to complete the excision of 
mesoappendix. All tumors were located at the tip of the 
appendix with a mean diameter of 0.6 cm (range: 0.3-1.0 
cm). No adjuvant therapy was performed. All patients 
were alive and disease-free during a mean follow-up of 
33 mo.
CONCLUSION: Appendiceal carcinoid tumor most of-
ten presents as appendicitis. In most cases, it is found 
incidentally during appendectomies and its diagnosis is 
rarely suspected before histological examination. Appen-
diceal carcinoid tumor can be managed by simple appen-
dectomy and resection of the mesoappendix, if its size is 
≤ 1 cm. 
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histological evidence of  carcinoid tumor of  the appendix. 
There were 4 male and 1 female patients with a mean age 
of  29.2 years (range: 6-82 years). Acute appendicitis was 
the clinical presentation for all patients. Open appendec-
tomy was performed in 4 patients and laparoscopic ap-
pendectomy in one. Histologically, all tumors were located 
at the tip of  the appendix with a mean diameter of  0.6 
cm (range: 0.3-1.0 cm). One patient was reoperated two 
months later to complete the excision of  mesoappendix 
after histological analysis. All patients were alive and dis-
ease-free during a mean follow-up of  33 mo (range: 21-49 
mo). Our results are summarized in Table 1.
DISCUSSION
Appendiceal carcinoid tumor is a unique carcinoid tumor 
and differs from those encountered elsewhere in the gas-
tro-intestinal system characterized by a relatively common 
frequency, small size of  the appendix, usually indolent be-
havior, occurrence in younger patients and a trend towards 
female predominance[6,7]. It accounts for 32%-57% of  all 
appendiceal tumors[6,8] in patients with a reported mean age 
of  42 years[9]. Surprisingly, there is a male predominance 
in our series (male/female: 4/1). Appendiceal carcinoid 
tumor lacks specifi c clinical features and its clinical pres-
entation may not differ from that of  acute appendicitis. It 
is usually diagnosed incidentally during surgery for acute 
appendicitis and occasionally during other abdominal pro-
cedures (colectomy, cholecystectomy, salpingectomy)[5,10]. 
In our series, the diagnosis of  all patients with symptoms 
of  acute appendicitis was made only after histological 
analysis of  the surgical specimen. Appendiceal carcinoid 
tumor exhibits little metastatic potential and therefore 
rarely presents with metastases[4,5]. Characteristics of  the 
tumor predicting aggressive behavior include size, histo-
logical subtype and mesoappendiceal involvement[3]. The 
predictive value of  tumour size is supported by many stud-
ies[4,11,12]. The calculated risk of  metastasis from tumors 
≤ 1 cm is zero, while a defi nite increase of  risk occurs 
with tumor size ≥ 2 cm, the rate of  metastasis ranges 
from 20%[13] to almost 85%[14]. In the present study, all the 
tumours were less than 1cm (mean diameter of  0.6 cm) 
and localized at the tip of  the appendix with no evidence 
of  regional or distant metastases. Appendiceal carcinoid 
tumor usually metastasizes to the regional lymph nodes 
rather than to the liver[15,16]. Carcinoid syndrome occurs in 
less than 10% of  patients with carcinoid tumor[17]. Clini-
cally, this syndrome develops when vasoactive substances 
produced by carcinoid tumor escape hepatic degradation 
and gain access into the systemic circulation. Its clinical 
features include cutaneous fl ushing, bronchoconstriction, 
diarrhea, and right-sided cardiac valvular fi brosis. This syn-
drome can be seen in appendiceal carcinoid tumor patients 
with liver metastases (< 2% of  all appendiceal carcinoid 
tumors)[10]. 
The vast majority of  appendiceal carcinoid tumor pa-
tients do not require any further procedure or investigation 
following appendectomy. Those who may benefit from 
additional screening are patients with high-grade malig-
nant tumor though smaller than 1 cm, patients with tumor 
of  between 1 cm and 2 cm or larger than 2 cm, and pa-
tients with incomplete resections and metastatic disease[3]. 
Plasma chromogranin A is the currently available most ac-
curate blood marker, with its level raised in 80%-100% of  
neuroendocrine tumor patients[18,19]. Other investigations 
include 24-h urinary levels of  5-hydroxyindoleacetic acid, 
computed tomography and 111In-labelled octreotide scin-
tigraphy.
Appendix tumor less than 1 cm in diameter is unlikely 
to be metastatic and may be managed with simple appen-
dectomy. Our five appendiceal carcinoid tumor patients 
underwent appendectomy. Reoperation was performed in 
1 patient two months later to complete the resection of  
mesoappendix, since histological analysis of  the surgical 
specimen showed an incomplete mesoappendix. There-
fore, consideration should be given to perform a complete 
mesoappendix resection during appendectomy. Appen-
diceal carcinoid tumor greater than 2 cm in size dem-
onstrates an increased incidence of  regional and distant 
spread and should be managed with a formal right hemi-
colectomy[17]. Controversy exists over the management fol-
lowing appendectomy, especially with regard to the role of  
right hemicolectomy in patients with tumor 1 to 2 cm in 
size[3]. Acceptable indications for right hemicolectomy in 
controversial cases have been recently suggested by Goede 
et al[3], including histological evidence of  mesoappendiceal 
extension, tumor at the base of  the appendix with positive 
margins or involvement of  the caecum, high-grade malig-
nant carcinoid tumor with a raised tumor prognostic index 
as measured by mitotic index and Ki67 levels. 
The management of  metastatic tumors and carcinoid 
syndrome has focused on cytoreductive chemotherapy 
and pharmacologic control of  the bioactive substances 
produced by these tumors[17]. Response rates less than 
40% have been reported for combined chemotherapy 
with streptozotocin and 5-fl uorouracil or doxorubicin but 
the response time is short and chemotherapy regimen has 
signifi cant side effects[20]. Thus, chemotherapy is not the 
fi rst choice of  treatment for patients with carcinoid tumor. 
Its use has to be discussed in a multidisciplinary approach 
related to other available treatments. The limited effi cacy 
of  systemic chemotherapy underlines the need to restrict 
its use in progressive cases or in patients with uncontrolled 
hormone-mediated symptoms despite biological or local 
treatment[20,21]. Octreotide, a somatostatin analog, is the 
most effective pharmacologic agent available to improve 
symptoms associated with carcinoid syndrome with a clini-
cal and biochemical response rate of  up to 60%. Available 
Table 1  Characteristics of 5 patients with appendiceal carcinoid 
tumor
Incidence (compared to appendectomy) 0.4%
Sex ratio (M/F) 4/1
Mean age (range) (yr) 29.2 (6-82)
 Location Tip of the appendix (100%)
Mean diameter (range) (cm) 0.6 (0.3-1.0)
Clinical feature Appendicitis
First procedure Appendectomy
Second procedure Resection of mesoappendix (1/5)
Mean follow-up (range) (mo) 33 (21-49)
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data on growth control indicate that stabilisation of  tumor 
growth seems to be the most benefi cial anti-proliferative 
effect occurring in up to 50% of  patients with slowly 
growing tumor. Partial tumor regression is marginal and 
occurs in only 3%-5% of  cases. The long-acting somato-
statin analogs are actually preferred[22].
Several studies on the antiproliferative effect of  
interferon-α in metastatic neuroendocrine tumor patients 
have reported that index hormone is reduced more than 
50% in 40%-60% of  patients with concomitant improve-
ment of  flushing and diarrhea. Stabilisation of  tumor 
growth is observed in 20%-40% and a reduction in tumour 
size in 12%-15% of  patients[23,24]. However, this therapeutic 
gain must be outweighed by the frequency and severity of  
toxic reactions[25]. Other treatment modalities such as local 
therapy and tumor-targeted radiotherapy are available for 
metastatic carcinoid tumor. Hepatic arterial chemoemboli-
zation (HACE) for non-resectable diffuse liver metastases 
could represent a good therapeutic option if  the disease is 
not under control with other available treatment modali-
ties[26,27]. HACE can be sued as a fi rst line treatment. By 
targeting somatostatin receptor-positive tumor, it is pos-
sible to deliver a tumoricidal dose of  radiation with 111In 
or 90Y coupled to somatostatin analogs. Preliminary studies 
in end-stage neuroendocrine tumor patients have shown 
promising results[28,29]. This treatment might be effective 
in patients refractory to conventional strategies and merits 
further development.
The prognosis of  appendiceal carcinoid tumor is much 
better than midgut carcinoid tumor[17]. The 5-year survival 
rate of  patients with local disease is reported to be 92% 
and 81% of  those with regional metastases, and 31% of  
those with distant metastases, respectively[1]. All the pa-
tients in our series were alive and disease-free during a 
mean follow-up of  33 mo.
In summary, appendiceal carcinoid tumor occurs most 
often as acute appendicitis. In most cases, it is found 
incidentally during appendectomies and its diagnosis is 
rarely suspected before histological examination. Although 
appendiceal carcinoid tumor has an excellent overall 
prognosis, consideration should be given to screening 
this group of  patients, since the frequency of  associated 
synchronous and metachronous colorectal cancer is high 
(13%-33%)[1,4,6,8]. 
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